<DOC>
	<DOCNO>NCT01745731</DOCNO>
	<brief_summary>This randomize controlled trial safety feasibility cell therapy medicinal product shall measure compare variable response treatment compare baseline prior implementation . Secondarily result obtain compare study group . Patients receive concomitant basic pharmacological treatment maintain liver function . All patient equally medically treat . The hypothetic test propose mononuclear cell bone marrow infuse territory hepatic portal remain segment ( II III ) perform contralateral portal embolization provide progenitor cell hepatic regenerative capacity would shorten time liver regeneration increase residual volume , facilitate realization extend hepatectomy great assurance maintain proper residual function adequate surgical margin .</brief_summary>
	<brief_title>Cell Infusion Intraportal Autologous Bone Marrow Mononuclear Enhancer Liver Regeneration</brief_title>
	<detailed_description>The study population correspond patient hepatic space occupy lesion require extend hepatic resection residual liver volume insufficient ensure liver function well require safety margin resection . The study population consist total 65 patient divide two group : Study group : patient hepatic space occupy lesion require extend hepatic resection undergo preoperative embolization segment portal intraportal affection application bone marrow cell . Control group : patient hepatic space occupy lesion require extend liver resection perform preoperatively embolization portal affect segment . The distribution case / control 1/1 . Patients study group surgery well portal embolization affect injury , receive experimental treatment test . Autologous bone marrow extract aspiration iliac crest local anesthesia , mononuclear cell ( mo-MNCs ) separate density gradient centrifugation Ficoll automatic procedure Laboratory Cell Therapy . In control group patient hold embolization liver segment locate lesion . It estimate inclusion period approximately 24 month plus follow-up patient twelve month . Thus total duration study thirty-six month entry first patient end monitoring period last patient include . The main objective evaluate safety feasibility autologous bone marrow mononuclear cell autologous liver regeneration enhancer , administer intraportal surgery patient liver space occupy lesion require extend hepatic resection residual liver volume insufficient ensure liver function safety margin require resection . Secondary objective : - Complications regenerative therapy / study procedure . - Increased volume obtain apply procedure liver regeneration surgery . - The percentage resection allow liver regeneration . - The liver functional status surgery . - The resection margin free tumor . Evaluation Methods : Radiological assessment liver volume . Analytical evaluation marker regeneration .</detailed_description>
	<criteria>1 . Patients sex age ≥ 18 year . 2 . Standard analytical parameter , define : Leukocytes ≥ 3000 Neutrophils ≥ 1500 Platelets ≥ 100,000 Aspartate aminotransferase ( AST ) / Alanine aminotransferase ( ALT ) ≤ 1.5 standard range institution creatinine ≤ 1.5 mg / dl 3 . Patients liver space occupy lesion ( LOE ) require extend hepatic resection . Patient selection cautious , cover basically 5 type liver damage must submit prior liver volumetry : Metastatic Disease subsidiary right hepatectomy extend segment IV Metastatic Disease subsidiary right hepatectomy suspect diseased liver ( neoadjuvant chemotherapy ) ( case doubt may use liver function test `` indocyanine green '' ) Bilobar liver metastases multiple nodule right lobe 3 nodule great 30 mm leave hepatic lobe ( LHI ) perform lumpectomy LHI + right portal branch ligation ( postoperative percutaneous embolization ) order make right hepatectomy 46 week ( `` two stage '' surgery ) Subsidiary Hepatocarcinoma extend right hepatectomy Liver Injury benign / malignant ( Hemangiomas , hydatid cyst liver tumor / primary bile hepatoblastoma ) , extension threatens viability remain liver tissue . 4 Patients give write informed consent participation study provide sufficient guarantee adherence protocol accord opinion investigator charge patient care . 1 . Different tumor record current disease disease hematologic . 2 . Patients uncontrolled hypertension . 3 . Severe heart failure ( NYHA IV ) . 4 . Patients malignant ventricular arrhythmia unstable angina . 5 . Diagnosis deep vein thrombosis previous 3 month . 6 . Adjunctive therapy include hyperbaric oxygen , vasoactive substance , agent angiogenesis inhibitor CoxII . 7 . BMI &gt; 40 kg/m2 . 8 . Patients alcoholic active alcoholism . 9 . Proliferative retinopathy . 10 . Concomitant disease reduce life expectancy less year . 11 . Difficulty monitoring . 12 . Heart failure ejection fraction ( EF ) &lt; 30 % . 13 . Stroke myocardial infarction within last 3 month . 14 . Pregnant woman woman childbearing age adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>